Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Firstwordpharma

Published November 13, 2026 · Updated November 14, 2026

Enveric Biosciences Reports Financial Results for Third Quarter 2026 and Provides ...

Read the full story at Firstwordpharma

Supported the FDA release of finalized guidance for clinical investigations of psychedelic and psychedelic -inspired therapeutics. CAMBRIDGE, Mass.

Surfaced by 2 Google Alerts

  • Psychedelics
  • Psychedelic biotech